Dr. Beumer is a tenured Professor of Pharmaceutical Sciences with a secondary appointment in the School of Medicine at the University of Pittsburgh, and holds the distinction of Diplomate of the American Board of Toxicology (DABT). He is intimately involved in the design, execution, supervision, and data analysis of PK and metabolic studies covering the entire spectrum of preclinical vitro-vivo, clinical phase 1, 2, 3, and post-marketing studies, with funding in each phase. Dr. Beumer is PI on one of only 3 NCI N02 Preclinical Pharmacology Contracts, mPI of one of the two U24 PK consortia supporting the NCI ETCTN efforts, and he is mPI of one of only 8 clinical ETCTN UM1 Grants, funding the Pittsburgh Cancer Consortium. He directs the Cancer Pharmacokinetics and Pharmacodynamics Facility (CPPF) of the UPMC Hillman Cancer Center (HCC), traditionally also the PK core of the NSABP-RTOG-GOG (NRG) and ALLIANCE. He currently serves as co-chair of the NCI Investigational Drug Steering Committee (IDSC), and its Pharmacology Task Force, and is a founding member of the TDM in oncology committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT).
Dr. Beumer has over 185 peer-reviewed publications, and has presented at national and international venues. He is also the Editor-in-Chief (U.S.) of the journal Cancer Chemotherapy and Pharmacology, and was awarded the 2021 Michaele Christian Oncology Drug Development Award and Lectureship by the National Cancer Institute Cancer Therapy Evaluation Program.
Dr. Beumer's interests are the development of anticancer agents partnering with both NCI and pharmaceutical partners, focusing on early trials that aim to study the pharmacology (PK/PD) of these novel agents (first-in man, mass balance, organ dysfunction, etc). His laboratory is able to support clinical trials with pharmacokinetic analyses by LC-MS/MS up to 14C analysis in a variety of samples from mass balance studies.
1998-2001 Member of the Honours Programme, University of Utrecht, Faculty of Pharmaceutical Science, Utrecht, The Netherlands
2007 Director’s Award for Scientific Excellence and Potential 2007, Nineteenth Annual University of Pittsburgh Cancer Institute Scientific Retreat, 3rd Place Award, Greensburg, PA
2007 Journal of Chromatography B top referee in 2006, Elsevier, Amsterdam, The Netherlands
2007 Hillman Fellows for Innovative Cancer Research Award, University of Pittsburgh Cancer Institute, Pittsburgh, PA
2009 Career Development Award. Phase I Study of ABT-888 in Combination with Gemcitabine in Patients with Advanced Malignancies. National Cancer Institute / Cancer Therapy Evaluation Program (NCI/CTEP), Bethesda, MD
2009 Hillman Fellows for Innovative Cancer Research Award, University of Pittsburgh Cancer Institute, Pittsburgh, PA
2010 Outstanding Faculty Honoree for dedication and talent in the areas of teaching, research, and public service. University of Pittsburgh, Pittsburgh, PA.
2012 The 2011 University of Pittsburgh Cancer Institute Junior Scholar Award in Clinical Cancer Research, University of Pittsburgh Cancer Institute, Pittsburgh, PA
2013 Outstanding Faculty Honoree for dedication and talent in the areas of teaching, research, and public service. University of Pittsburgh, Pittsburgh, PA.
2021 Merrill J. Egorin Excellence in Scientific Leadership Award. UPMC Hillman Cancer Center, Pittsburgh, PA
2021 Michaele Christian Oncology Drug Development Award and Lectureship. National Cancer Institute – Cancer Therapy Evaluation Program, Bethesda, MD